Network Bio

About Network Bio

Network Bio is a biotechnology company that builds disease-specific AI models from large-scale human biological data to advance personalized medicine. The company, which launched in August 2026 with $50 million in financing, was co-founded by CEO Asad Ali Ahmad, PhD, Raphael Potter, and Hani Goodarzi, PhD. Investors include Section 32, Thiel Bio, Founders Fund, and Breyer Capital. Network Bio's business model centers on creating a unified research network from the fragmented biobanks of major U.S. academic medical centers, including Mass General Brigham, the University of Pennsylvania, and the University of Colorado Anschutz. Network Bio sources, links, and structures patient-derived tissues, paired blood samples, molecular information, and longitudinal clinical outcomes. By applying common quality standards and data harmonization, it creates 'AI-ready' datasets at a scale unattainable by a single institution. This proprietary data foundation is then used to train its bio-native AI architecture, which is designed to learn biological principles that can be transferred across different diseases. The primary service is providing these AI models to partners, such as pharmaceutical companies and healthcare systems, for use in diagnostics, biomarker discovery, patient stratification, and drug development. The company has secured early commercial validation with a co-development and licensing agreement valued at over $30 million with an undisclosed Fortune 100 healthcare company. Additionally, Network Bio has a major partnership with NVIDIA to develop a cell-free RNA foundation model, aiming to use non-invasive liquid biopsies to gain insights into tissue biology. The platform has demonstrated its potential in studies related to respiratory, ovarian, and bone diseases. The company's ultimate goal is to create a 'General Medical Intelligence' capable of understanding disease biology at a fundamental level.